Contact this trialFirst, we need to learn more about you.
AKT Inhibitor
Capivasertib + Docetaxel for Prostate Cancer
Recruiting1 awardPhase 3
Cerritos, California
This trial will compare the effect of two different treatments for metastatic prostate cancer. One group will receive a combination of capivasertib and docetaxel, while the other group will receive docetaxel and a placebo. The goal is to see if adding capivasertib to docetaxel improves survival rates.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service